...
首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >Study on prevalence of hepatitis B in pregnant women and its effect on maternal and fetal outcome at tertiary care centre
【24h】

Study on prevalence of hepatitis B in pregnant women and its effect on maternal and fetal outcome at tertiary care centre

机译:三级医疗中心孕妇乙型肝炎的流行及其对母婴结局的影响研究

获取原文

摘要

Background: Hepatitis-B is caused by double stranded DNA virus. Prevalence of hepatitis B in pregnant woman worldwide is 2.5 to 1.5% whereas in India it is 2 to 7.7%. Methods: This is a retrospective study conducted at SAMC and PGI, Indore between January 2016 to December 2016. Hepatitis- B prevalence and outcome was assessed by doing routine screening of hepatitis B antigen in our indoor patients and finding out their maternal and fetal outcome. Results: Total 3567 deliveries were conducted during study period, out of them 39 were diagnosed as HbsAg positive pregnant patient; so, prevalence was found to be 1.09%. out of these, 84.6% were booked cases, mode of delivery was vaginal in 66.67% cases, preterm Delivery was in 10.26% of cases, meconium stained liquor was found in 5.13% cases, maternal mortality was nil, perinatal mortality was found in 2.56% cases and 5.13% cases were admitted in NICU. Conclusions: Screening of all pregnant women for HbsAg irrespective of risk factors will definitely help to know the correct prevalence and reduce the transmission of hepatitis B infection. Hepatitis B is a major public health problem in India and will continue to be until appropriate nationwide vaccination programs and other control measures are established.
机译:背景:乙型肝炎是由双链DNA病毒引起的。全世界孕妇的乙型肝炎患病率为2.5%至1.5%,而印度为2%至7.7%。方法:这是一项回顾性研究,于2016年1月至2016年12月在印多尔的SAMC和PGI进行。通过常规筛查室内患者的乙型肝炎抗原并找出其母婴结局,评估了乙型肝炎的患病率和结局。结果:在研究期间共进行了3567例分娩,其中39例被诊断为HbsAg阳性孕妇。因此,患病率为1.09%。在这些患者中,有84.6%的患者为预订患者,分娩方式为阴道分娩的占66.67%病例,早产的比例为10.26%,胎粪污染的液体为5.13%,产妇死亡率为零,围产期死亡率为2.56新生儿重症监护病房(ICU)收治的%病例和5.13%病例。结论:对所有孕妇进行HbsAg筛查,无论其危险因素如何,都绝对有助于了解正确的患病率并减少乙型肝炎感染的传播。乙型肝炎是印度的主要公共卫生问题,并将在建立适当的全国性疫苗接种计划和其他控制措施之前持续存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号